EBS
Emergent BioSolutions Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
4.49
close · 2026-08-13
value
100
cheaper than peers100
quality
23
stronger fundamentals23
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
34 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 0.67× | 98 |
| forward P/E | 1.50× | 98 |
| EV to EBITDA | 4.89× | 94 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -1.6% | 55 |
| operating margin | 6.8% | 46 |
| debt to equity | 111.8% | 40 |
| revenue growth | -29.7% | 8 |
4 of 4 measures available
Facts
| market cap | $230M |
| free cash flow | $256.2M |
| employees | 900 |
| first trade | 2006-11-15 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-06 |